Drug Trial Radar · NCT03199950
PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel
Last checked: Nov 20, 2026Latest source record: Jun 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,366
Planned (sponsor's estimate)
Start
Jun 23, 2017
Primary completion
Nov 23, 2018
Study completion Nov 23, 2018
Sponsor
- Lead sponsor
- Zuyderland Medisch CentrumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The hospital pharmacy at the Zuyderland Medical Centre developed the DElirium MOdel (DEMO) to predict which patients are at risk of developing a delirium in patients aged 60 or older. With this delirium risk prediction model we aim to predict more accurately which patients are at high risk of developing a delirium and want to investigate if these patients can benefit from prophylactic haloperidol.
Conditions
- Delirium
Interventions
HaloperidolDrug
Haloperidol 2dd1mg (08.00am - 10.00pm)
Placebo Oral TabletDrug
Placebo oral 2dd (08.00am - 10.00pm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurence of deliriumTime frame: Delirium within 5 days postoperative
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zuyderland Medisch Centrum
Sittard, Limburg, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.